U.S. FDA Approves Padcev plus Keytruda or Keytruda Qlex as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
RegulatoryapprovedPadcevKeytrudaKeytruda QlexPositive
AI Analysis
Summary
Pfizer and Astellas announced FDA approval of Padcev combined with Keytruda or Keytruda Qlex for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer, regardless of cisplatin eligibility status.
Outcome Details
FDA approved Padcev plus Keytruda or Keytruda Qlex as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer regardless of cisplatin eligibility
Importance:8/10
Sentiment:
0.90
FDA approvaloncologybladder cancerneoadjuvantadjuvantcombination therapy
Read the original article
Published by Drugs.com New Drug Approvals on July 10, 2026 4:07 AM